Brief: Vicore Pharma Q3 EBIT SEK -60.1 Million
05/11/2024 07:00
Nov 05 (Reuters) - Vicore Pharma Q3 adjusted free cash flow SEK -87.3 million. * Q3 net income SEK -60 million * Q3 adjusted EPS SEK -0.54 * Q3 sales SEK 0 * Q3 cash & investments SEK 380.4 million
Recent news on Vicore Pharma Holding AB
See all newsBrief: Vicore Pharma Holding Q3 Net Revenues Amounted To Sek 0.6 Mln
Brief: Vicore Pharma Holding AB Phase 2B Aspire Trial Of Buloxibutid In Ipf Passes Pre-Planned Futility Analysis, On Track For Mid-2027 Topline Results
Brief: Vicore Pharma Q2 Operating Loss At SEK 150.1 Million
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:53 PM
Brief: Vicore Pharma Shares Start Trading In US On July 2